Tsuka Pharmaceutical Scientists Have Been Developing Significant Expertise In Using The Berkeley Lights Technology And Workflows Specifically News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon system for antibody discovery,as well as cell and gene therapy and cell line development research. Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical scientists have been developing significant expertise in using the Berkeley Lights technology and workflows. Specifically, the Beacon Platform has enabled them to expand their antibody discovery capacity beyond traditional hybridoma techniques. On top of the antibody discovery expertise, Otsuka will be leveraging the Beacon technology and workflows for use in the challenging field of cell and gene therapy. With the use of the Beacon system for research in cell and gene therapy, they can work rapidly and efficiently towards new discoveries. Yue Geng, Ph.D, general manager ....

United States , Yue Geng , Otsuka Pharmaceuticals , Prnewswire Berkeley Lights Inc , Berkeley Lights , Beacon Platform , Otsuka Pharmaceutical , Berkeley Lights Platform , July 26 , 022 Prnewswire Berkeley Lights , Nc Nasdaq Bli , A Leader In Digital Cell Biology , Oday Announced Otsuka Pharmaceuticals , A Leading Pharmaceutical Company , As Implemented The Use Of Berkeley Lights Beacon System For Antibody Discovery , As Well Cell And Gene Therapy Line Development Research Since Acquiring The Beacon Platform In October 2021 , Tsuka Pharmaceutical Scientists Have Been Developing Significant Expertise In Using The Berkeley Lights Technology And Workflows Specifically , He Beacon Platform Has Enabled Them To Expand Their Antibody Discovery Capacity Beyond Traditional Hybridoma Techniques On Top Of The Expertise , Tsuka Will Be Leveraging The Beacon Technology And Workflows For Use In Challenging Field Of Cell Gene Therapy With System Research , Hey Can Work Rapidly And Efficiently Towards New Discoveries Yue Geng , Jh D , Eneral Manager And Senior Vice President Of The Platform Business At Berkeley Lights , Uot Otsuka Pharmaceutical And Their Scientists Area Great Example Ofa Team Fully Leveraging The Beacon Platform Capabilities In Multiple Scientific Disciplines They Have Demonstrated Themselves Asa Leader Competitive Pharma Market Through Dedication Learning Advanced Technologies Systems We Value Partnership To Research Using Our For Success Of Customers Quot About Berkeley Lights Isa Leading Digital Cell Biology Company Focused On Enabling Accelerating Rapid Development Commercialization Biotherapeutics Other Based Products Captures Deep Phenotypic , Nd Genotypic Information For Thousands Of Single Cells In Parallel And Can Also Deliver The Live Biology Customers Desire Form Best Our Platform Isa Fully Integrated , Nd To End Solution , Omprising Proprietary Consumables ,